The dermatoses of pregnancy represent a distinct heterogenous group of cutaneous disorders that can impact the health of the pregnant woman and potentially the fetus. The current classification of pregnancy-specific cutaneous disorders is reviewed, along with important clinical features. Advances in management of these disorders, along with fetal implications, are discussed. The diagnosis of these disorders is challenging, but important clinical features can aid in diagnosis. There have been important advances in the management of these disorders and better understanding of potential fetal risks. Early recognition is critical for appropriate care.
BackgroundRosacea is one of the most common cutaneous disorder characterized primarily by facial flushing, erythema, papules, pustules, telangiectases, and nasal swelling. Diagnosis of rosacea is principally done by a physical examination and a consistent patient history. However, qualitative human assessment is often subjective and suffers from a relatively high intra‐ and inter‐observer variability in evaluating patient outcomes.Materials and MethodsTo overcome these problems, we propose a quantitative and reproducible computer‐aided diagnosis system, Ros‐NET, which integrates information from different image scales and resolutions in order to identify rosacea lesions. This involves adaption of Inception‐ResNet‐v2 and ResNet‐101 to extract rosacea features from facial images. Additionally, we propose to refine the detection results by means of facial‐landmarks–based zones (ie, anthropometric landmarks) as regions of interest (ROI), which focus on typical areas of rosacea occurrence on a face.ResultsUsing a leave‐one‐patient‐out cross‐validation scheme, the weighted average Dice coefficients, in percentages, across all patients (N = 41) with 256 × 256 image patches are 89.8 ± 2.6% and 87.8 ± 2.4% with Inception‐ResNet‐v2 and ResNet‐101, respectively.ConclusionThe findings from this study support that pre‐trained networks trained via transfer learning can be beneficial in identifying rosacea lesions. Our future work will involve expanding the work to a larger database of cases with varying degrees of disease characteristics.
Background
Chronic graft-versus-host disease (GVHD) may present with various cutaneous manifestations. Isolated case reports describe eruptive angiomas in this setting.
Objective
To provide a clinical and pathologic description of vascular proliferations in patients with GVHD.
Methods
Cases of documented GVHD associated with vascular proliferations were collected from the National Institutes of Health, Ohio State University, and MD Anderson Cancer Center.
Results
11 patients with a diagnosis of GVHD who developed vascular proliferations were identified. All patients manifested sclerotic type chronic GVHD of the skin. Vascular lesions were first documented a median of 44 months after transplant and occurred primarily on the lower extremities or trunk. Histopathology revealed anastomosing networks of thin-walled vascular proliferations in a vague lobular growth pattern, with overlying epidermal acanthosis, peripheral collarette, ulceration, and disorganized fibroblast-rich and fibrotic stroma. Improvement was noted in one patient treated with propranolol and sirolimus and one patient with electrocautery.
Limitations
Given the retrospective nature of the study, the overall incidence of vascular lesions in patients with GVHD is unknown. Histopathology was present for review on only 3/11 patients. Conclusion: The phenomenon of vascular lesions appears to be relatively specific for sclerotic type chronic GVHD when compared to other fibrosing diseases. We propose the term GVHD-associated angiomatosis to describe this entity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.